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Our previous studies have shown that Baicalin could effectively inhibit Chlamydia trachomatis in vitro. 
In this study, Baicalin was tested for potential antichlamydial activity using a murine genital Chlamydia 
trachomatis infection model. It was demonstrated that Baicalin significantly reduced C. trachomatis 
loading in BALB/c mice that were vaginally infected with the pathogen. On the basis of these data and 
our previous observations, we concluded that further evaluation of Baicalin for prevention and 
treatment of sexually transmitted chlamydial infection is warranted. 
 





Chlamydia trachomatis is primarily a human pathogen 
associated with common sexually transmitted diseases 
and trachoma. Most developing countries that have the 
highest burden of chlamydial infections have limited 
capacity to effectively screen for chlamydial infections 
and treatment is thus largely based on symptomatic case 
ascertainment (Schachter, 1999; Behets et al., 2001). 
Studies demonstrated that the majority of infected 
individuals do not seek treatment because they have no 
or very mild symptoms (Westrom and Mardh, 1983). 
Without proper treatment, about one-third of infected 
individuals develop long-term, devastating complications, 
such as infertility and chronic pelvic inflammatory pain 
syndrome (Laga et al., 1994). Infected individuals are 
also at increased risk of HIV acquisition, owing to ulcerative 
damages that occur in the epithelial tissues. The medical 
and financial burdens of these conditions call for the 
development of new strategies to effectively prevent C. 
trachomatis infection (Ridgway, 1997).  
Although effective antimicrobial treatment is available, 
this has been largely unsuccessful in halting the spread 
of infection, most likely due to the high rate of asymptomatic 
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antibiotic resistant strains of Chlamydia have also been 
reported recently (Somani et al., 2000). Furthermore, it 
has been suggested that antibiotic treatment can result in 
persistent infections with aberrant forms of C. trachomatis 
that may be reactivated at a later date. 
We have reported previously that Baicalin can effec-
tively inhibit C. trachomatis in vitro (Huang et al., 2009). 
In the present investigation, we studied the in vivo thera-
peutic effects of Baicalin using a mouse experimental 




MATERIALS AND METHODS 
 
C. trachomatis serovar D (Department of Pathogenic Biology, 
Tongji Medical College, Huazhong University of Science and 
Technology, Wuhan, China) was cultured in HeLa cells as 
described previously (Rasmussen et al., 1997). The infectivity of the 
chlamydia was expressed as the number of inclusion forming units. 
Baicalin (HPLC Content > 98.0%) from Chongqing Green Valley 
Bio-tech Co. LTD. (Chongqing, China). Medroxyprogesterone was 
used to make mice susceptible to infection (Amit et al., 2009). 
Eight-week-old Balb/c female mice were injected subcutaneously 
with the hormone (2.5 mg/mouse) 2 weeks before infection. The 
injection was repeated 7 days before infection. The progesterone-
treated animals were given intravaginally either 15 ml of 1 mM 
Baicalin prepared in 50 mM Hepes buffer (pH 7.0) or the vehicle 
Hepes buffer (10 mice in each group). One hour later, the animals 
were infected intravaginally with C. trachomatis (2 × 107 IFUs per 
mouse). After infection, intravaginal administration of Baicalin or 
vehicle was repeated three times per day. 5, 11, 16 and 19 days 
after infection,  vaginal  swabs  were  taken.  Infectious  elementary  




Table 1. Summary statistics for EB counts of vaginal swabs. 
 
 
Mean (standard deviation) Geometric mean Percent reduction of Chlamydial load 
Baicalin vehicle Baicalin vehicle Baicalin vehicle 
Day 5 169,478.0 (104,163.4) 784,962.0 (879.145.2) 107,579.6 684,647.3   
Day 11 511.9 (648.7) 812,254.7 (956,553,2) 321.4 75,691.8 99.7 88.9 
Day 16 97.5 (165.3) 97,563.7 (103,478,1) 18.7 11,568.9 99.8 98.3 




bodies on the swabs were eluted into 1.0 ml sucrose phosphate-
glutamate buffer, serially diluted and inoculated onto HeLa cells 
grown on coverslips. After 30 h of culture, coverslips were fixed with 




RESULTS AND DISCUSSION 
 
It is now widely accepted that C. trachomatis is the most 
prevalent sexually transmitted pathogen. Classical anti-
biotics are undesirable for long-term, prophylactic use 
because they frequently disrupt normal microflora and 
consequently increase the risk for bacterial vaginosis. 
Among non antibiotic reagents tested against C. tracho-
matis, only one offered partial protection in vivo; others 
were either ineffective or even worsened the infection in 
vivo although, in vitro, they demonstrated adverse effects 
on the pathogen. 
Baicalin, being a medicinal plant traditionally used in 
Oriental medicine, is a flavonoid derived from Scutellariae 
Radix and known to have various biological functions, 
including antimicrobial activities including antimicrobial, 
anti-inflammatory activities, and also shown to have the 
therapeutic potential for the treatment of atherosclerosis 
and restenosis (Gao et al.,1999). Previous studies showed 
that Baicalin can inhibit infection in vitro by several strains 
of Chlamydia pneumoniae (Liu et al., 2006). We pre-
viously also characterized the inhibition of C. trachomatis 
in cell culture by Baicalin (Huang et al., 2009).  
The objective of the present study is to investigate 
whether Baicalin would also inhibit chlamydial infection in 
vivo. Here, we tested the effects of Baicalin on C. 
trachomatis infection in vivo using a MoPn vaginal 
infection model previously established in BALB/c mice. 
Table 1 apparently revealed that the majority of control 
vehicle-treated mice had higher bacterial loadings as 
compared with Baicalin-treated animals. The findings 
from this study further confirmed that Baicalin significantly 
reduced C. trachomatis loading in BALB/c mice that were 
vaginally infected with the pathogen and suggested that 
Baicalin deserved further evaluation as antichlamydial 
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